Business
Catalyst Pharmaceuticals Announces Multiple Abstracts on FYCOMPA® (Perampanel) from Eisai Co, Ltd., to be Presented at the 35th International Epilepsy Congress
CORAL GABLES, Fla., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric
About this update from Catalyst Pharmaceuticals, Inc.
[{"type":"text","content":"CORAL GABLES, Fla., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (\"Catalyst\") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, today announced that multiple abstracts highlighting FYCOMPA® (perampanel) CIII will be presented at the upcoming 35th International Epilepsy Congress (“IEC”) taking place on September 2 – 6, 2023 in Dublin, Ireland. These are presentations by Eisai Co., Ltd. (\"Eisai\"), which holds the rights to FYCOMPA in countries and regions outside the U.S. Some abstracts will also be considered for publication in Epilepsia following the IEC. The accepted abstracts and presentations detail the results from clinical and real-world studies, further documenting the uses of perampanel in both focal and generalized epilepsy across a diverse range of patients. “These findings, which are being presented at IEC, further validate and add to the growing body of evidence supporting the benefits of perampanel in the treatment of seizure disorders,” said Gary Ingenito, MD, PhD, Chief Medical and Regulatory Officer of Catalyst. “We are pleased this investigative work will be presented at such a prestigious forum.” Details of the Accepted Abstracts are as follows: Title: Perampanel for Treatment of Focal and Generalised Epilepsy in Everyday Clinical Practice: Evidence from PERMIT 2Authors: Eugen Trinka, Robert Wechsler, Wendyl D’Souza, Tony Wu, Imad Najm, Leock Ngo, Rob McMurray, Vicente VillanuevaOral Presentation number: 370Oral Presentation Session Name: Drug Therapy 1Session: Sunday, September 3, 2023, at 3:30 PM-4:30 PM BST(Eugen Trinka will present for 10 minutes: 3:35 PM-3:45 PM)Presenter: Eugen TrinkaLocation: Room Liffey B Title: Study 603: Analysis of Effectiveness and Safety of Perampanel in a Multicentre, Retrospective Study in Patients from Korea with Focal-Onset Seizures who Converted to MonotherapyAuthors: Sung Chul Lim, Won Gu Lee, Dong Wook Kim, Kwang Ki Kim, Young-Min Shon, Jihyun Park, Yoona Lee, Dae-Won SeoPoster number: P048Digital Poster* Session and Rapid-Fire Presentation Name: Drug Therapy 2Rapid Fire Presentation (2-minute session):Time and Date: Sunday, September 3, 2023, at 2:00 PM-2:30 PM BSTPresenter: Sung Chul LimLocation: Dig...